US-based pharmaceutical firm Ischemix has enrolled the first patient in a Phase IIa trial of its lead compound CMX-2043 to prevent contrast-induced acute kidney injury (CI-AKI) in acute coronary syndrome patients undergoing coronary angiography (the CARIN trial).

CMX-2043 is a chemically-modified, naturally-occurring molecule with an excellent safety profile that has showed efficacy in a prior human clinical trial.

Brigham and Women’s Hospital Heart & Vascular Center Interventional Cardiovascular Programs executive director and CARIN trial lead investigator Deepak Bhatt said: "The CARIN trial presents an exciting opportunity to study the potential of CMX-2043 to treat cardiac patients who are at serious risk of complications."

"The CARIN trial presents an exciting opportunity to study the potential of CMX-2043 to treat cardiac patients who are at serious risk of complications."

Around 240 patients will be enrolled in the CARIN trial, which will evaluate the ability of CMX-2043 to prevent CI-AKI.

In the US, approximately 500,000 coronary angiography patients are at high-risk of developing CI-AKI and currently there are no approved drug therapies for the same.

The trial will also seek to confirm the results of its prior Phase IIa trial, where CMX-2043 prevented peri-procedural cardiac injury in patients undergoing a percutaneous coronary intervention (PCI).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Ischemix intends to announce data from the CARIN trial in mid-2015, when it plans to initiate discussions with prospective corporate partners.

The company believes that CMX-2043 has the opportunity to address indications with in excess of a billion dollars of potential revenues, while producing a net cost savings to the health care system.

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now